Kiseke Platform
The Kiseke Platform is a pioneering solution in regenerative medicine, designed to harness the full potential of exosome biotherapeutics. Utilizing perinatal derived Mesenchymal Signaling Cells (MSC), this state-of-the-art platform offers a scalable, cGMP-compliant method for producing high-quality, cell-free exosome therapies. These exosomes are enriched with a unique blend of anti-inflammatory, anti-oxidative, immunomodulatory, and growth factors, making them ideal for promoting tissue growth and repair across a wide range of therapeutic applications.
At the heart of the Kiseke Platform is our advanced 3D hollow fiber bioreactor system, meticulously designed to emulate the natural in vivo cellular environment. This innovative approach not only maintains the functional characteristics of MSCs but also enhances the potency and quality of the exosomes produced. The platform further integrates a series of proprietary processes for isolating, cultivating, and preconditioning MSCs, ensuring batch-to-batch uniformity and the highest standard of exosome therapy production.
The purification and quality control of the exosomes are managed through a combination of ultrafiltration, size exclusion chromatography, affinity chromatography, and other cutting-edge purification methods. Additionally, our platform employs a comprehensive suite of advanced analytical methodologies, including quantitative phase imaging, nanopore RNA sequencing, hyperspectral imaging, microfluidic resistive pulse sensing, LC-MS/MS, and machine learning-enhanced tools, to thoroughly characterize both MSCs and exosomes.
AI for Precision Medicine Applications
The Kiseke Platform stands as a beacon of innovation in regenerative medicine, paving the way for new therapeutic possibilities and advancing the frontier of exosome-based treatments. It's not just a platform; it's a promise of a healthier, regenerated future.
Machine learning
Manufacturing + Advanced Analytics
Exosome Therapeutics